Literature DB >> 11911424

Cure of pulmonary Rhizomucor pusillus infection in a patient with hairy-cell leukemia: role of liposomal amphotericin B and GM-CSF.

B Ma1, J F Seymour, H Januszewicz, M A Slavin.   

Abstract

We describe a case of successfully treated multifocal pulmonary Rhizomucor pusillus, a condition which has previously been universally fatal. A 77 year-old man had a background of chronic neutropenia due to hairy-cell leukemia, splenectomy, corticosteroid therapy and an obstructing left ureteric transitional-cell carcinoma. He was successfully treated with 3 months of high-dose liposomal amphotericin B and 7 months of granulocyte-macrophage colony-stimulating factor. Treatment was complicated by mild reversible deterioration of renal function. There was a near complete radiological response to the therapy at 6 months and the patient remains well 20 months following diagnosis of R. pusillus and 13 months following cessation of treatment.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11911424     DOI: 10.3109/10428190109097768

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  8 in total

Review 1.  Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species.

Authors:  Marisa Z R Gomes; Russell E Lewis; Dimitrios P Kontoyiannis
Journal:  Clin Microbiol Rev       Date:  2011-04       Impact factor: 26.132

2.  In Vivo and In Vitro Impairments in T Helper Cell and Neutrophil Responses against Mucor irregularis in Card9 Knockout Mice.

Authors:  Lingyue Sun; Shuzhen Zhang; Zhe Wan; Ruoyu Li; Jin Yu
Journal:  Infect Immun       Date:  2021-04-16       Impact factor: 3.441

3.  Molecular identification of Rhizomucor pusillus as a cause of sinus-orbital zygomycosis in a patient with acute myelogenous leukemia.

Authors:  Peter C Iwen; Alison G Freifeld; Lynne Sigler; Stefano R Tarantolo
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

Review 4.  Human Fungal Pathogens of Mucorales and Entomophthorales.

Authors:  Leonel Mendoza; Raquel Vilela; Kerstin Voelz; Ashraf S Ibrahim; Kerstin Voigt; Soo Chan Lee
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-06       Impact factor: 6.915

Review 5.  Recent advances in the management of mucormycosis: from bench to bedside.

Authors:  Brad Spellberg; Thomas J Walsh; Dimitrios P Kontoyiannis; John Edwards; Ashraf S Ibrahim
Journal:  Clin Infect Dis       Date:  2009-06-15       Impact factor: 9.079

6.  Zygomycosis in Immunocompromised non-Haematological Patients.

Authors:  George Petrikkos; Miranda Drogari-Apiranthitou
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-03-15       Impact factor: 2.576

7.  Sargramostim (rhu GM-CSF) as Cancer Therapy (Systematic Review) and An Immunomodulator. A Drug Before Its Time?

Authors:  Hillard M Lazarus; Carolyn E Ragsdale; Robert Peter Gale; Gary H Lyman
Journal:  Front Immunol       Date:  2021-08-17       Impact factor: 7.561

Review 8.  New insights on mucormycosis and its association with the COVID-19 pandemic.

Authors:  Mona G Alshahawey; Ghadir S El-Housseiny; Noha S Elsayed; Mohammad Y Alshahrani; Lamia Mel Wakeel; Khaled M Aboshanab
Journal:  Future Sci OA       Date:  2021-12-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.